Tamoxifen downregulates connective tissue growth factor to ameliorate peritoneal fibrosis

Blood Purification

Volumn 31, Issue 4, 2011, Pages 252-258

  Huang, Jenq Wen ^a   Yen, Chung Jen ^a   Wu, Hon Yen ^a   Chiang, Chih Kang ^a   Cheng, Hui Teng ^a   Lien, Yu Chung ^a   Hung, Kuan Yu ^a   Tsai, Tun Jun ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Animal model; Connective tissue growth factor; Peritoneal dialysis; Peritoneal fibrosis; Tamoxifen

Indexed keywords

COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOWN REGULATION; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MESOTHELIUM; MESOTHELIUM CELL; NONHUMAN; PERITONEAL FIBROSIS; PERITONEUM CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; QUANTITATIVE ANALYSIS; RAT; THICKNESS;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CELLS, CULTURED; COLLAGEN TYPE I; CONNECTIVE TISSUE GROWTH FACTOR; DOWN-REGULATION; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; HUMANS; MALE; PERITONEAL FIBROSIS; RATS; RATS, WISTAR; SODIUM HYPOCHLORITE; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA;

EID: 78651400159     PISSN: 02535068     EISSN: 14219735     Source Type: Journal    
DOI: 10.1159/000322255     Document Type: Article

References (25)

1. Honda K, Hamada C, Nakayama M, Miyazaki M, Sherif AM, Harada T, Hirano H: Impact of uremia, diabetes, and peritoneal dialysis itself on the pathogenesis of peritoneal sclerosis: a quantitative study of peritoneal membrane morphology. Clin J Am Soc Nephrol 2008;3:720-728.
2. Lo WK, Kawanishi H: Encapsulating peritoneal sclerosis - medical and surgical treatment. Perit Dial Int 2009;29 (Suppl 2):S211-S214.
3. Kawanishi H, Kawaguchi Y, Fukui H, Hara S, Imada A, Kubo H, Kin M, Nakamoto M, Ohira S, Shoji T: Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study. Am J Kidney Dis 2004;44:729-737. (Pubitemid 39237618)
4. Balasubramaniam G, Brown EA, Davenport A, Cairns H, Cooper B, Fan SL, Farrington K, Gallagher H, Harnett P, Krausze S, Steddon S: The Pan-Thames EPS study: treatment and outcomes of encapsulating peritoneal sclerosis. Nephrol Dial Transplant 2009;24:3209-3215.
5. Guest S: Tamoxifen therapy for encapsulating peritoneal sclerosis: mechanism of action and update on clinical experiences. Perit Dial Int 2009;29:252-255.
6. Lien YC, Kuo CC, Liu KL, Hung KY, Huang TM, Huang JW: Clinical images: encapsulating peritoneal sclerosis. CMAJ 2009;181:177.
7. Swartz RD: Idiopathic retroperitoneal fibrosis: a review of the pathogenesis and approaches to treatment. Am J Kidney Dis 2009;54:546-553.
8. Akram S, Pardi DS, Schaffner JA, Smyrk TC: Sclerosing mesenteritis: clinical features, treatment, and outcome in ninety-two patients. Clin Gastroenterol Hepatol 2007;5:589-596, quiz 523-584.
9. Savelli BA, Parshley M, Morganroth ML: Successful treatment of sclerosing cervicitis and fibrosing mediastinitis with tamoxifen. Chest 1997;111:1137-1140. (Pubitemid 27171497)
10. Buck MB, Knabbe C: TGF-beta signaling in breast cancer. Ann NY Acad Sci 2006;1089:119-126. (Pubitemid 47092079)
11. Margetts PJ, Bonniaud P, Liu L, Hoff CM, Holmes CJ, West-Mays JA, Kelly MM: Transient overexpression of TGF-beta1 induces epithelial mesenchymal transition in the rodent peritoneum. J Am Soc Nephrol 2005;16:425-436. (Pubitemid 41725138)
12. Yang AH, Chen JY, Lin JK: Myofibroblastic conversion of mesothelial cells. Kidney Int 2003;63:1530-1539. (Pubitemid 36350019)
13. Hung KY, Chen CT, Huang JW, Lee PH, Tsai TJ, Hsieh BS: Dipyridamole inhibits TGF-beta-induced collagen gene expression in human peritoneal mesothelial cells. Kidney Int 2001;60:1249-1257.
14. Hung KY, Huang JW, Chen CT, Lee PH, Tsai TJ: Pentoxifylline modulates intracellular signalling of TGF-beta in cultured human peritoneal mesothelial cells: implications for prevention of encapsulating peritoneal sclerosis. Nephrol Dial Transplant 2003;18:670-676.
15. Hung KY, Shyu RS, Fang CC, Tsai CC, Lee PH, Tsai TJ, Hsieh BS: Dipyridamole inhibits human peritoneal mesothelial cell proliferation in vitro and attenuates rat peritoneal fibrosis in vivo. Kidney Int 2001;59:2316-2324.
16. Fang CC, Lai MN, Chien CT, Hung KY, Tsai CC, Tsai TJ, Hsieh BS: Effects of pentoxifylline on peritoneal fibroblasts and silica-induced peritoneal fibrosis. Perit Dial Int 2003;23:228-236.
17. Levine S, Saltzman A: Abdominal cocoon: an animal model for a complication of peritoneal dialysis. Perit Dial Int 1996;16:613-616. (Pubitemid 127541302)
18. Tsai TJ, Yen CJ, Fang CC, Yang CC, Lee PH, Yen TS: Effect of intraperitoneally administered agents on human peritoneal mesothelial cell growth. Nephron 1995;71:23-28.
19. Hung KY, Chen CT, Yen CJ, Lee PH, Tsai TJ, Hsieh BS: Dipyridamole inhibits PDGF-stimulated human peritoneal mesothelial cell proliferation. Kidney Int 2001;60:872-881.
20. Hung KY, Wu KD, Tsai TJ: In vitro study of peritoneal fibrosis. Perit Dial Int 2007;27(Suppl 2):S72-S75.
21. Lonn P, Moren A, Raja E, Dahl M, Moustakas A: Regulating the stability of TGFbeta receptors and Smads. Cell Res 2009;19:21-35.
22. Grainger DJ, Metcalfe JC: Tamoxifen: teaching an old drug new tricks? Nat Med 1996;2:381-385.
23. Fraser D: Smad7: at the interface of TGF-beta and proinflammatory signaling. Perit Dial Int 2007;27:523-525.
24. Matsuoka H, Tsubaki M, Yamazoe Y, Ogaki M, Satou T, Itoh T, Kusunoki T, Nishida S: Tamoxifen inhibits tumor cell invasion and metastasis in mouse melanoma through suppression of PKC/MEK/ERK and PKC/PI3K/Akt pathways. Exp Cell Res 2009;315:2022-2032.
25. Hung KY, Huang JW, Chiang CK, Tsai TJ: Preservation of peritoneal morphology and function by pentoxifylline in a rat model of peritoneal dialysis: molecular studies. Nephrol Dial Transplant 2008;23:3831-3840.